Table 3.
Body Composition of Patients With Acromegaly Before and After Biochemical Control of Acromegaly and of Controls
| Variable | Acromegaly Pretherapy (n = 20) | Acromegaly Posttherapy (n = 16) | Controls (n = 20) | P Value Acromegaly Pretherapy vs Controls | P Value Acromegaly Pretherapy vs Posttherapy | P Value Acromegaly Posttherapy vs Controls |
|---|---|---|---|---|---|---|
| BMI, kg/m2 | 30.4 ± 5.4 | 30.8 ± 6.5 | 30.5 ± 5.9 | 0.9 | 0.2 | 0.9 |
| SAT CSA at L1-2, cm2a | 130 (66, 219) | 169 (118, 229) | 199 (89, 322) | 0.2 | 0.0006 | 0.6 |
| VAT CSA at L1-2, cm2a | 74 (49, 204) | 113 (73, 229) | 138 (55, 229) | 0.4 | 0.0002 | 0.9 |
| SAT CSA at L4, cm2a | 217 (170, 365) | 275 (225, 419) | 293 (174, 489) | 0.3 | 0.002 | 0.9 |
| VAT CSA at L4, cm2a | 96 (62, 188) | 122 (76, 213) | 140 (56, 208) | 0.5 | <0.0001 | 0.9 |
| Proximal femur muscle CSA, cm2 | 240 ± 62 | 232 ± 77 | 216 ± 46 | 0.2 | 0.09 | 0.4 |
| Proximal femur SAT CSA, cm2a | 238 (166, 276) | 273 (155, 294) | 263 (190, 337) | 0.3 | 0.03 | 0.5 |
| Midfemur muscle CSA, cm2 | 162 ± 38 | 154 ± 45 | 158 ± 40 | 0.9 | 0.002 | 0.8 |
| Midfemur SAT CSA, cm2a | 96 (56, 113) | 100 (58, 130) | 113 (68, 133) | 0.09 | 0.006 | 0.5 |
| Intrahepatic lipids, lipid/watera | 0.02 (0.01, 0.04) | 0.03 (0.01, 0.30) | 0.06 (0.02, 0.22) | 0.03 | 0.03 | 0.6 |
| IMCL/SOL, AUa | 8.2 (3.9, 11.2) | 8.3 (6.4, 11.6) | 10.7 (6.4, 14.1) | 0.2 | 0.9 | 0.3 |
Data are presented as mean ± standard deviation for normally distributed data and as median (interquartile range) for nonnormally distributed data. P values in boldface are significant.
Abbreviations: AU, arbitrary unit; SOL, soleus muscle.
a
Nonnormally distributed data.